AGN – Allergan plc – Fundamental analysis, financial statements, key ratios, and fair value analysis

Allergan plc

Healthcare
Drug Manufacturers – Specialty & Generic
142.57
6.5
4.78%
193.46
129.82
Stock Current Price
Change
Change %
52 Week High
52 Week Low

Financial Ratios

Earnings per Share (EPS)6.57
EPS Estimate Currrent Qtr4.14
Book Value Per Share209.04
Market Cap 48 Billion
PE Ratio 19.7
Dividend Yield2.1587586

Stock Yield

Stock Return 7 Days2.30%
Stock Return 15 Days-10.47%
Stock Return 30 Days -16.00%
Stock Return 3 Months-31.34%
Stock Return One Year-21.33%
Stock Return 3 Years-20.82%

Stock Technical Analysis

Relative Strengh Index (14)23.34
Average True Range (14)5.14
Momentum (14)-16.2
Simple Moving Average (14) -16.2
Time Series Forecast (14)126.48
Time Series Forecast (30) 154.51

Stock News

NewsSourcePublished
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc. of Class Action Lawsuit and Upcoming Deadline– AGNYahoo Finance01/05/2019 14:00
ALLERGAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan plc. – AGNYahoo Finance01/05/2019 03:50
Biotechs lead broad market advance, XBI up 5%Seeking Alpha01/04/2019 13:11
Why Allergan (AGN) Could Beat Earnings Estimates AgainYahoo Finance01/04/2019 15:10
Ironwood/Allergan Settle Linzess Patent Litigation With MylanYahoo Finance01/03/2019 15:27
SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) and Lead Plaintiff Deadline: February 19, 2019Yahoo Finance01/03/2019 14:55
New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of ActionYahoo Finance01/03/2019 12:45
The Daily Biotech Pulse: Aevi’s ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With AmgenYahoo Finance01/03/2019 12:36
Allergan to Report Fourth Quarter and Full Year 2018 Earnings and Host Conference Call and WebcastYahoo Finance01/03/2019 12:30
10 Bargain Stocks Amid Market’s WreckageYahoo Finance01/03/2019 12:09
Healthcare: Specter of ACA Repeal Hangs Over Fairly Valued SectorYahoo Finance01/03/2019 11:00
Corrections & AmplificationsYahoo Finance01/03/2019 00:53
Drugmakers ring in the new year by hiking prices on hundreds of drugsYahoo Finance01/02/2019 23:19
Allergan and Ironwood settle Linzess patent litigation with MylanSeeking Alpha01/02/2019 16:29
Biopharmas Restrained In Drug Pricing For 2019 — With These ExceptionsYahoo Finance01/02/2019 21:28

Financial Statements

index2014201520162017
Revenue5 Billion13 Billion15 Billion16 Billion
Cost of Revenue2 Billion3 Billion2 Billion2 Billion
Gross Profit3 Billion10 Billion13 Billion14 Billion
Gross Margin (%)63.55%78.31%87.23%86.40%
Selling General and Administrative Expense2 Billion4 Billion5 Billion5 Billion
Other operating expenses2 Billion2 Billion-6 Billion18 Billion
Earning Before Interest and Taxes EBIT-2 Billion4 Billion14 Billion-10 Billion
EBIT/Operating Margin (%)-0.00%27.61%98.64%-100.00%
Interest Expense412 Million1 Billion1 Billion1 Billion
Other non-operating expenses/income0000
Earnings before Tax-2 Billion2 Billion13 Billion-11 Billion
Income Tax Expense-514 Million-2 Billion-2 Billion-7 Billion
Net Income-2 Billion4 Billion15 Billion-4 Billion
Net Margin (%)-0.00%30.86%102.76%-0.00%
Earnings per share from operating income-00.08937220.0251397-0
Earnings per Diluted Share-710.0138.18-13
Dividends per Basic Common Share0.20.102.8
Payout ratio-37100.1NA-5
Weighted average number of shares outstanding220 Million391 Million392 Million313 Million
index2017 Q42018 Q12018 Q22018 Q3
Revenue4 Billion4 Billion4 Billion4 Billion
Cost of Revenue581 Million523 Million482 Million597 Million
Gross Profit4 Billion3 Billion4 Billion3 Billion
Gross Margin (%)86.57%85.76%88.32%84.74%
Selling General and Administrative Expense1 Billion1 Billion1 Billion1 Billion
Other operating expenses3 Billion3 Billion3 Billion2 Billion
Earning Before Interest and Taxes EBIT-534 Million-718 Million-248 Million396 Million
EBIT/Operating Margin (%)-0.00%-0.00%-0.00%10.12%
Interest Expense263 Million251 Million230 Million220 Million
Other non-operating expenses/income0000
Earnings before Tax-797 Million-968 Million-478 Million176 Million
Income Tax Expense-4 Billion-682 Million-5 Million213 Million
Net Income3 Billion-286 Million-472 Million-38 Million
Net Margin (%)72.15%-0.00%-0.00%-0.00%
Earnings per share from operating income-0-3-094.9628
Earnings per Diluted Share9.09-1-1-0
Dividends per Basic Common Share0.70.720.720.72
Payout ratio12.9857-1-2-0
Weighted average number of shares outstanding343 Million289 Million340 Million345 Million
index2014201520162017
Cash and Equivalents250 Million1 Billion2 Billion2 Billion
Trade and Non Trade Receivables1 Billion2 Billion3 Billion3 Billion
Inventory985 Million758 Million718 Million904 Million
Other current assets5 Billion7 Billion16 Billion9 Billion
Current Assets7 Billion9 Billion18 Billion11 Billion
Total Non-Current Assets46 Billion127 Billion111 Billion107 Billion
Total Assets53 Billion136 Billion129 Billion118 Billion
Trade and Non Trade Payables3 Billion4 Billion5 Billion6 Billion
Other current liabilities2 Billion4 Billion3 Billion4 Billion
Current Liabilities5 Billion8 Billion8 Billion10 Billion
Liabilities Non Current19 Billion51 Billion45 Billion35 Billion
Accumulated Retained Earnings Deficit-198 Million4 Billion18 Billion13 Billion
Shareholder’s equity other29 Billion73 Billion58 Billion61 Billion
Shareholders Equity28 Billion77 Billion76 Billion74 Billion
Noncontrolling interests10 Billion17 Billion16 Billion20 Billion
Total Assets53 Billion136 Billion129 Billion118 Billion
index2017 Q42018 Q12018 Q22018 Q3
Cash and Equivalents2 Billion995 Million2 Billion1 Billion
Trade and Non Trade Receivables3 Billion3 Billion3 Billion3 Billion
Inventory904 Million948 Million922 Million895 Million
Other current assets9 Billion4 Billion4 Billion3 Billion
Current Assets11 Billion6 Billion6 Billion6 Billion
Total Non-Current Assets107 Billion106 Billion103 Billion101 Billion
Total Assets118 Billion112 Billion109 Billion107 Billion
Trade and Non Trade Payables6 Billion5 Billion5 Billion5 Billion
Other current liabilities4 Billion744 Million1 Billion2 Billion
Current Liabilities10 Billion6 Billion6 Billion6 Billion
Liabilities Non Current35 Billion34 Billion31 Billion30 Billion
Accumulated Retained Earnings Deficit13 Billion13 Billion12 Billion12 Billion
Shareholder’s equity other61 Billion60 Billion59 Billion59 Billion
Shareholders Equity74 Billion72 Billion71 Billion71 Billion
Noncontrolling interests20 Billion12 Billion12 Billion12 Billion
Total Assets118 Billion112 Billion109 Billion107 Billion
index2014201520162017
Net Cash Flow from Operations2 Billion5 Billion1 Billion6 Billion
Capital Expenditure-225 Million-315 Million-298 Million-343 Million
Net Cash Flow from Investing-5 Billion-37 Billion24 Billion-878 Million
Net Cash Flow from Financing3 Billion33 Billion-25 Billion-5 Billion
Cash and Equivalents250 Million1 Billion2 Billion2 Billion
index2017 Q42018 Q12018 Q22018 Q3
Net Cash Flow from Operations2 Billion1 Billion1 Billion1 Billion
Capital Expenditure-115 Million-35 Million-60 Million-46 Million
Net Cash Flow from Investing-796 Million3 Billion702 Million504 Million
Net Cash Flow from Financing-1 Billion-5 Billion-1 Billion-2 Billion
Cash and Equivalents2 Billion995 Million2 Billion1 Billion

Stock Price History

table